Incidence and prevalence of COVID-19 cases (×100,000 population) in Emilia-Romagna, Italy, between February 24, 2020, and May 31, 2020.

Source: Dipartimento della protezione civile. (DOCX)</p

Association of demographic/clinical characteristics, process indicators and study period (pre-/post-pandemic) with 30-day mortality following hip fracture among patients admitted to the hospital in March, Emilia-Romagna, Italy.

Association of demographic/clinical characteristics, process indicators and study period (pre-/post-pandemic) with 30-day mortality following hip fracture among patients admitted to the hospital in March, Emilia-Romagna, Italy.</p

Hip-fracture surgery, length of stay, and rehabilitation by year and month of the year, Emilia-Romagna, Italy.

Hip-fracture surgery, length of stay, and rehabilitation by year and month of the year, Emilia-Romagna, Italy.</p

Thirty-day mortality following hip fracture by year and month of the year, Emilia-Romagna, Italy.

Thirty-day mortality following hip fracture by year and month of the year, Emilia-Romagna, Italy.</p

Demographic and clinical characteristics of the study population, by year and month of the year, Emilia-Romagna, Italy.

Demographic and clinical characteristics of the study population, by year and month of the year, Emilia-Romagna, Italy.</p

Supporting data.

(XLS)</p

Additional file 1: of Impact of postoperative complications on long-term survival following surgery for T4 colorectal cancer

Table S1. Additional organs resected with T4 colorectal cancer. (DOCX 17 kb

Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma

Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and lethal neoplasms in humans, and just limited progresses have been made to extend patient survival and decrease ATC-associated mortality. Thus, the identification of novel therapeutic strategies for treating ATC is needed. Recently, our group has identified two proteins with oncogenic activity, namely HMGA1 and EZH2, with pivotal roles in ATC cancer progression. Therefore, we tested the ability of trabectedin, a HMGA1-targeting drug, and GSK126, an inhibitor of EZH2 enzymatic activity, to impair cell viability of four ATC-derived cell lines. In the present study, we first confirmed the overexpression of HMGA1 and EZH2 in all ATC-derived cell lines and tissues compared to the normal primary thyroid cells and tissues. Then, treatment of the ATC cell lines with trabectedin and GSK126 resulted in a drastic induction of apoptotic cell death, which increased when the ATC cell lines were treated with a combination of both drugs. Conversely, normal primary human thyroid cells did not show any significant reduction in their viability when exposed to the same drugs. Noteworthy, both drugs induced the deregulation of EZH2- and HMGA1-controlled genes. Altogether, these findings propose the combination of trabectedin and GSK126 as possible novel strategy for ATC therapy.</p

Supplemental material for Characterization of inflammatory infiltrate of ulcerative dermatitis in C57BL/6NCrl-Tg(HMGA1P6)1Pg mice

Supplemental Material for Characterization of inflammatory infiltrate of ulcerative dermatitis in C57BL/6NCrl-Tg(HMGA1P6)1Pg mice by Davide De Biase, Francesco Esposito, Marco De Martino, Claudio Pirozzi, Antonio Luciano, Giuseppe Palma, Giuseppina Mattace Raso, Valentina Iovane, Stefania Marzocco, Alfredo Fusco and Orlando Paciello in Laboratory Animals</p

Metabolite profiling of SM03 by UHPLC-HRMS.

This table indicates putative molecular formula based on HRMS1 spectra, cross searched with a custom database built from the Dictionary of Natural Products, with a selection restricted to natural products occurring in cyanobacteria, green and red algae.</p